At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...
A study presented at the San Antonio Breast Cancer Symposium examined whether tumor mutational burden (TMB) was associated with outcomes in hormone receptor-positive, HER2-negative metastatic breast ...